Table 1.
Evaluation of clinical characteristics of C. krusei candidemia cases in paediatric ward
| C. krusei | C. tropicalis | C. pelliculosa | C. krusei versus C. tropicalisp value | C. krusei versus C. pelliculosap value | |
|---|---|---|---|---|---|
| (n = 82) | (n = 36) | (n = 27) | |||
| No. (%) | No. (%) | No. (%) | |||
| Neonates | |||||
| Total | 65 (79.3) | 25 (69.4) | 22 (81.5) | 0.248 | 0.804 |
| Males | 47 (72.4) | 17 (68) | 16 (72.7) | ||
| Females | 18 (27.6) | 8 (32) | 6 (27.3) | ||
| Children | |||||
| Total | 17 (20.7) | 11 (30.6) | 5 (18.5) | 0.248 | 0.804 |
| Males | 11 (64.7) | 6 (54.5) | 5 (100) | ||
| Females | 6 (35.3) | 5 (45.5) | 0 (0) | ||
| Age [median (IQR)] | 13 days (6–28 days) | 14 days (4–112 days) | 13 days (2–28 days) | 0.865 | 0.296 |
| Days to positivity to blood culture (median, IQR) | 2 (1–4) days | 5 (1–13.75) days | 1 (1–3) days | 0.007* | 0.794 |
| Underlying disease | |||||
| Congenital malformations | 14 (17.1) | 16 (44.4) | 1 (3.7) | 0.002* | 0.248 |
| Gastrointestinal | 20 (24.4) | 15 (41.7) | 1 (3.7) | 0.059 | 0.018* |
| Late onset neonatal sepsis | 28 (34.1) | 11 (30.6) | 8 (29.6) | 0.703 | 0.665 |
| Early onset neonatal sepsis | 10 (2.8) | 1 (2.8) | 5 (18.5) | 0.095 | 0.297 |
| Neurological | 13 (15.9) | 4 (11.1) | 4 (14.8) | 0.499 | 0.584 |
| Jaundice | 4 (4.9) | 2 (5.6) | 0 (0) | 0.596 | 0.314 |
| Cardiac | 3 (3.7) | 2 (5.6) | 1 (3.7) | 0.484 | 0.686 |
| Renal | 1 (1.2) | 0 (0) | 2 (7.4) | 0.695 | 0.151 |
| Infection | 5 (6.1) | 3 (8.3) | 3 (11.1) | 0.463 | 0.312 |
| Gastroenteritis | 5 (6.1) | 1 (2.8) | 1 (3.7) | 0.404 | 0.537 |
| Tetanus | 0 (0) | 1 (2.8) | 1 (3.7) | 0.305 | 0.248 |
| Risk factors | |||||
| Prematurity | 9 (11) | 3 (8.3) | 3 (11) | 0.754 | 0.613 |
| ALL | 0 (0) | 1 (2.8) | 0 (0) | 0.305 | - |
| ICU admission | 19 (23.2) | 17 (47.2) | 2 (7.4) | 0.009* | 0.072 |
| Iatrogenic risk factors | |||||
| Urinary catheter | 5 (6.1) | 2 (5.6) | 0 (0) | 0.637 | 0.234 |
| Central line catheter | 1 (1.2) | 3 (8.3) | 0 (0) | 0.084 | 0.752 |
| Nasogastric/orogastric tube | 9 (11) | 7 (19.4) | 4 (14.8) | 0.171 | 0.407 |
| Endotracheal tube | 6 (7.3) | 3 (8.3) | 0 (0) | 0.556 | 0.173 |
| Mechanical ventilation | 15 (18.3) | 16 (44.4) | 2 (7.4) | 0.003* | 0.147 |
| Antibiotics | 24 (29.3) | 13 (36.1) | 2 (7.4) | 0.461 | 0.021* |
| Vancomycin | 15 (18.3) | 8 (22.2) | 1 (3.7) | 0.620 | 0.052 |
| Piperacillin–tazobactam | 3 (3.7) | 1 (2.8) | 1 (3.7) | 0.643 | 0.686 |
| Aminoglycosides | 15 (18.3) | 5 (13.9) | 2 (7.4) | 0.557 | 0.147 |
| Carbapenems | 16 (19.5) | 7 (19.4) | 1 (3.7) | 0.993 | 0.039* |
| Cephalosporins | 8 (9.8) | 1 (2.8) | 1 (3.7) | 0.176 | 0.294 |
| Metronidazole | 2 (2.4) | 4 (11.1) | 1 (3.7) | 0.069 | 0.578 |
| Erythromycin | 2 (2.4) | 0 (0) | 0 (0) | 0.481 | 0.564 |
| Mortality | 17 (23) | 15 (42.9) | 4 (14.8) | 0.033* | 0.371 |
ALL acute lymphoblastic leukaemia, ICU intensive care unit, IQR interquartile range, italicized words in the first column indicates the group under which different factors/parametes were analysed
*Statistically significant